Iannis E Adamopoulos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4171212/publications.pdf

Version: 2024-02-01

172386 110317 4,504 67 29 64 citations g-index h-index papers 68 68 68 7131 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Peripheral Î ³ δT Cells Regulate Neutrophil Expansion and Recruitment in Experimental Psoriatic Arthritis. Arthritis and Rheumatology, 2022, 74, 1524-1534.	2.9	17
2	Bromodomain-containing-protein-4 and cyclin-dependent-kinase-9 inhibitors interact synergistically in vitro and combined treatment reduces post-traumatic osteoarthritis severity in mice. Osteoarthritis and Cartilage, 2021, 29, 68-77.	0.6	13
3	Axial spondyloarthritis: new advances in diagnosis and management. BMJ, The, 2021, 372, m4447.	3.0	71
4	IL-23 reshapes kidney resident cell metabolism and promotes local kidney inflammation. Journal of Clinical Investigation, $2021,131,.$	3.9	33
5	Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. Dermatology and Therapy, 2021, 11, 385-400.	1.4	29
6	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq0 0 0 rgBT /Overlock	10 Дf _{.3} 50 5	42 Td (editior 1,430
7	A site-specific map of the human plasma glycome and its age and gender-associated alterations. Scientific Reports, 2020, 10, 17505.	1.6	14
8	Psoriatic arthritis under the influence of IFNÎ ³ . Clinical Immunology, 2020, 218, 108513.	1.4	10
9	Systemic lupus erythematosus favors the generation of IL-17 producing double negative T cells. Nature Communications, 2020, 11, 2859.	5.8	59
10	Psoriatic arthritis; overcoming the challenges by creating opportunities. Clinical Immunology, 2020, 218, 108519.	1.4	3
11	IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong?. Frontiers in Immunology, 2020, 11, 623874.	2.2	16
12	$\hat{I}^{3}\hat{I}$ T cells in rheumatic diseases: from fundamental mechanisms to autoimmunity. Seminars in Immunopathology, 2019, 41, 595-605.	2.8	12
13	Interleukinâ€17A and Pathologic New Bone Formation: TheÂMyth of Prometheus Revisited. Arthritis and Rheumatology, 2019, 71, 483-485.	2.9	2
14	Go with the flowâ€"hidden vascular passages in bone. Nature Metabolism, 2019, 1, 173-174.	5.1	8
15	Compendium of synovial signatures identifies pathologic characteristics for predicting treatment response in rheumatoid arthritis patients. Clinical Immunology, 2019, 202, 1-10.	1.4	21
16	2D Visualization of the Psoriasis Transcriptome Fails to Support the Existence of Dual-Secreting IL-17A/IL-22 Th17 T Cells. Frontiers in Immunology, 2019, 10, 589.	2,2	12
17	Transcriptome mining and B cell depletion support a role for B cells in psoriasis pathophysiology. Journal of Dermatological Science, 2019, 96, 181-184.	1.0	3
18	Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight. Clinical Immunology, 2019, 206, 15-22.	1.4	28

#	Article	IF	Citations
19	Ca2+-Dependent Regulation of NFATc1 via KCa3.1 in Inflammatory Osteoclastogenesis. Journal of Immunology, 2018, 200, 749-757.	0.4	30
20	Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23 Receptor Enables Recruitment of the Shared Receptor IL-12R \hat{l}^2 1. Immunity, 2018, 48, 45-58.e6.	6.6	95
21	Inflammation in bone physiology and pathology. Current Opinion in Rheumatology, 2018, 30, 59-64.	2.0	94
22	$\hat{I}^3\hat{I}$ TCR regulates production of interleukin-27 by neutrophils and attenuates inflammatory arthritis. Scientific Reports, 2018, 8, 7590.	1.6	17
23	Meta-analysis of RNA sequencing datasets reveals an association between TRAJ23, psoriasis, and IL-17A. JCI Insight, 2018, 3, .	2.3	29
24	Autophagy and autoimmunity. Clinical Immunology, 2017, 176, 55-62.	1.4	96
25	Loss of WDFY3 ameliorates severity of serum transfer-induced arthritis independently of autophagy. Cellular Immunology, 2017, 316, 61-69.	1.4	1
26	Critical Role of LTB4/BLT1 in IL-23–Induced Synovial Inflammation and Osteoclastogenesis via NF-κB. Journal of Immunology, 2017, 198, 452-460.	0.4	36
27	K Ca 3.1 as Master Regulator in Inflammatory Osteoclastogenesis. Biophysical Journal, 2017, 112, 547a.	0.2	0
28	Concise Review: Stem Cells in Osteoimmunology. Stem Cells, 2017, 35, 1461-1467.	1.4	43
29	CD4+ virtual memory: Antigen-inexperienced T cells reside in the $na\tilde{A}^-$ ve, regulatory, and memory T cell compartments at similar frequencies, implications for autoimmunity. Journal of Autoimmunity, 2017, 76-88.	3.0	24
30	Targeting IL-17 in psoriatic arthritis. European Journal of Rheumatology, 2017, 4, 272-277.	1.3	32
31	Autophagy-linked FYVE containing protein WDFY3 interacts with TRAF6 and modulates RANKL-induced osteoclastogenesis. Journal of Autoimmunity, 2016, 73, 73-84.	3.0	18
32	T Cell–Independent Mechanisms Associated with Neutrophil Extracellular Trap Formation and Selective Autophagy in IL-17A–Mediated Epidermal Hyperplasia. Journal of Immunology, 2016, 197, 4403-4412.	0.4	38
33	Interactions of the Immune System with Skin and Bone Tissue in Psoriatic Arthritis: A Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2016, 51, 87-99.	2.9	31
34	The critical role of toll-like receptors â€" From microbial recognition to autoimmunity: A comprehensive review. Autoimmunity Reviews, 2016, 15, 1-8.	2.5	226
35	Autoimmune or autoiflammatory? Bad to the bone. International Journal of Clinical Rheumatology, 2015, 10, 5-7.	0.3	3
36	Antiâ€kelchâ€like 12 and antiâ€hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver International, 2015, 35, 642-651.	1.9	66

#	Article	IF	CITATIONS
37	Crosstalk among IL-23 and DNAX Activating Protein of 12 kDa–Dependent Pathways Promotes Osteoclastogenesis. Journal of Immunology, 2015, 194, 316-324.	0.4	38
38	Alternative pathways of osteoclastogenesis in inflammatory arthritis. Nature Reviews Rheumatology, 2015, 11, 189-194.	3.5	104
39	IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1284-1292.	0.5	76
40	Leukotriene B4 activates intracellular calcium and augments human osteoclastogenesis. Arthritis Research and Therapy, 2014, 16, 496.	1.6	17
41	The IL-23/IL-17 axis in psoriatic arthritis. Autoimmunity Reviews, 2014, 13, 496-502.	2.5	132
42	Loss of Wdfy3 in mice alters cerebral cortical neurogenesis reflecting aspects of the autism pathology. Nature Communications, 2014, 5, 4692.	5.8	74
43	A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders. Journal of Visualized Experiments, 2014, , .	0.2	5
44	The emerging role of Interleukin 27 in inflammatory arthritis and bone destruction. Cytokine and Growth Factor Reviews, 2013, 24, 115-121.	3.2	29
45	The Implication of Vitamin D and Autoimmunity: a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2013, 45, 217-226.	2.9	229
46	<scp>NKG</scp> 2C, <scp>HLA</scp> â€E and their association with psoriasis. Experimental Dermatology, 2013, 22, 797-799.	1.4	12
47	A Mutation in Mouse Paklipl Causes Orofacial Clefting while Human PAKlIPl Maps to 6p24 Translocation Breaking Points Associated with Orofacial Clefting. PLoS ONE, 2013, 8, e69333.	1.1	10
48	Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6. Journal of Autoimmunity, 2012, 39, 369-376.	3.0	21
49	Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity, 2011, 44, 243-252.	1.2	49
50	IL-23 Is Critical for Induction of Arthritis, Osteoclast Formation, and Maintenance of Bone Mass. Journal of Immunology, 2011, 187, 951-959.	0.4	176
51	Myeloid DAP12-associating lectin (MDL)-1 regulates synovial inflammation and bone erosion associated with autoimmune arthritis. Journal of Experimental Medicine, 2010, 207, 579-589.	4.2	80
52	Structural, cellular, and molecular evaluation of bone erosion in experimental models of rheumatoid arthritis: Assessment by \hat{l} /4CT, histology, and serum biomarkers. Autoimmunity, 2010, 43, 642-653.	1.2	9
53	Interleukin-17A upregulates receptor activator of NF- \hat{l}° B on osteoclast precursors. Arthritis Research and Therapy, 2010, 12, R29.	1.6	242
54	Immune regulation of bone loss by Th17 cells. Arthritis Research and Therapy, 2008, 10, 225.	1.6	68

#	Article	IF	Citations
55	Fine mapping of the MHC Class III region demonstrates association of AIF1 and rheumatoid arthritis. Rheumatology, 2008, 47, 1761-1767.	0.9	39
56	A novel computational method to quantify and analyse osteoclastic bone resorption. Journal of Computational Methods in Sciences and Engineering, 2008, 7, 87-91.	0.1	0
57	Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma. British Journal of Cancer, 2007, 96, 1716-1722.	2.9	37
58	Hepatocyte growth factor can substitute for M-CSF to support osteoclastogenesis. Biochemical and Biophysical Research Communications, 2006, 350, 478-483.	1.0	45
59	Bishosphonates inhibit bone resorption in multicentric reticulohistiocytosis. Bone, 2006, 38, 65.	1.4	1
60	Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis. Human Pathology, 2006, 37, 1176-1185.	1.1	31
61	Hepatocyte Growth Factor in Normal and Diseased Bone and Joint Tissues. Current Rheumatology Reviews, 2006, 2, 1-7.	0.4	4
62	Synovial fluid macrophages are capable of osteoclast formation and resorption. Journal of Pathology, 2006, 208, 35-43.	2.1	84
63	Stimulation of osteoclast formation by inflammatory synovial fluid. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 69-77.	1.4	19
64	In vitro biodegradation of three brushite calcium phosphate cements by a macrophage cell-line. Biomaterials, 2006, 27, 4557-4565.	5.7	94
65	LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 1451-1462.	6.7	89
66	Macrophage-mediated biodegradation of poly(DL-lactide-co-glycolide)in vitro. Journal of Biomedical Materials Research - Part A, 2006, 79A, 582-590.	2.1	25
67	Hepatocyte Growth Factor in Normal and Diseased Bone and Joint Tissues. Current Rheumatology Reviews, 2006, 2, 1-7.	0.4	4